SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events. A live audio webcast of the events will be availab ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events. A live audio webcast of the events will be availab ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy function ...

Dr. Knobelman was previously chief financial officer and head of corporate development for Senti Bio, a biotechnology company that utilized a synthetic biology platform to enable programming of next-generation cell therapies. At Senti, Dr. Knobelman took the company public in 2022 and was responsible for investor relations, accounting, strategic finance, financial planning and analysis, facilities, legal, portfolio management, and corporate and business development. Prior to Senti, Dr. Knobelman served in i ...

Core Viewpoint - Kronos Bio, Inc. (KRON) is experiencing significant selling pressure but is positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Stock Performance - KRON has declined by 5.6% over the past four weeks, indicating a downward trend [1]. - The Relative Strength Index (RSI) for KRON is at 26.49, suggesting that the stock is oversold and may be due for a rebound [2][3]. Group 2: Analyst Sentiment - There is strong consensus among Wall Street analysts that KRON will report better earnings than previously predicted, with a 4.8% increase in consensus EPS estimates over the last 30 days [3]. - KRON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a turnaround [3].

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.28%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.43, delivering a surprise of 15.69%.Over the last four quarters, the company has surpas ...

Financial Performance - The net loss for Q1 2024 was $30.0 million, or $0.50 per share, compared to a net loss of $26.2 million, or $0.46 per share in Q1 2023[11]. - Total operating expenses for Q1 2024 were $34.5 million, an increase of approximately 16.0% from $29.7 million in Q1 2023[11]. - Research and development expenses for Q1 2024 were $14.2 million, down from $19.7 million in Q1 2023, reflecting a decrease of approximately 27.5%[9]. - General and administrative expenses for Q1 2024 were $7.5 million, compared to $10.1 million in Q1 2023, a reduction of about 25.0%[11]. - The company incurred an impairment of long-lived assets expense of $6.6 million and restructuring expenses of $6.2 million in Q1 2024[9]. Cash Position - Kronos Bio reported a cash runway of $152.0 million, expected to last into the second half of 2026[1]. Assets and Equity - Total assets as of March 31, 2024, were $182.98 million, down from $213.28 million as of December 31, 2023[13]. - Total stockholders' equity decreased to $136.97 million as of March 31, 2024, from $159.08 million at the end of 2023[13]. Future Plans - The company anticipates completing IND-enabling studies for KB-9558 by the end of 2024, with the first patient dosing expected in the first half of 2025[2]. - Kronos Bio plans to present updated study data from the ongoing Phase 1/2 trial of KB-0742 at the upcoming ASCO conference in June 2024[4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 (650) 781-5200 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) (Former name, former address and former fiscal year, if changed since last report) ☐ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investme ...